Dimensional Fund Advisors LP Purchases 834 Shares of Insulet Co. (NASDAQ:PODD)

Dimensional Fund Advisors LP increased its position in Insulet Co. (NASDAQ:PODDFree Report) by 0.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 124,280 shares of the medical instruments supplier’s stock after purchasing an additional 834 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.18% of Insulet worth $26,968,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Parkside Financial Bank & Trust lifted its holdings in shares of Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 123 shares during the period. Wolff Wiese Magana LLC raised its holdings in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 134 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new position in shares of Insulet in the fourth quarter valued at about $34,000. Lindbrook Capital LLC raised its holdings in shares of Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 75 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new position in shares of Insulet in the fourth quarter valued at about $43,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PODD shares. Raymond James cut their price target on Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Piper Sandler lowered their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Stifel Nicolaus lifted their price objective on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Canaccord Genuity Group lifted their price objective on Insulet from $226.00 to $234.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Finally, Jefferies Financial Group lifted their price objective on Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $239.18.

Check Out Our Latest Stock Report on PODD

Insulet Trading Up 0.7 %

NASDAQ:PODD opened at $177.19 on Monday. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $298.95. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75. The stock has a market capitalization of $12.41 billion, a PE ratio of 53.69, a price-to-earnings-growth ratio of 3.19 and a beta of 1.00. The business’s 50-day simple moving average is $172.59 and its 200-day simple moving average is $185.18.

Insulet (NASDAQ:PODDGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business had revenue of $441.70 million for the quarter, compared to analysts’ expectations of $424.05 million. During the same quarter in the previous year, the business posted $0.23 EPS. Insulet’s revenue for the quarter was up 23.3% on a year-over-year basis. Sell-side analysts expect that Insulet Co. will post 3.11 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Timothy J. Scannell sold 3,300 shares of Insulet stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total transaction of $596,970.00. Following the transaction, the director now owns 42,586 shares in the company, valued at approximately $7,703,807.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.47% of the stock is currently owned by company insiders.

Insulet Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Featured Articles

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.